Bristol-Myers Squibb Company (BMY)
Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings?
Bristol Myers is looking to turn its business around, banking on the strong uptake of new drugs. However, the 2025 outlook is not bright and we recommend investors to wait and watch for now.
Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?
At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.
BMY Down on Heart Drug Camzyos Failure in Late-Stage Study
Bristol Myers phase III study evaluating Camzyos for the treatment of adult patients with non-obstructive hypertrophic cardiomyopathy fails to meet its dual-primary endpoints.
Bristol Myers' heart disease drug fails to meet main goals in late-stage study
Bristol Myers Squibb said on Monday its experimental drug to treat a type of heart disease did not meet the main goals in a late-stage study.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here's Why Bristol Myers Squibb (BMY) Gained But Lagged the Market Today
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $53.78, denoting a +1.34% change from the preceding trading day.
BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo
Bristol Myers gets FDA approval for Opdivo monotherapy and Opdivo plus Yervoy combination for colorectal cancer in the first-line setting.
Bristol Myers wins dismissal of lawsuit alleging Pomalyst monopoly
Bristol Myers Squibb won the dismissal of a proposed class action accusing it of fraudulently obtaining patents and filing sham patent lawsuits to maintain an illegal monopoly on its blockbuster blood cancer drug Pomalyst, keeping cheaper generic versions off the market.
Hedge Funds Are Dumping Tech Stocks: Grab These 4 Safety Net High-Yield Dividend Giants Now
Hedge funds are rapidly reducing their exposure to global information technology stocks, with the latest selloff marking the fastest decline in six months.
Is Bristol Myers Squibb's High-Yielding Dividend Safe?
High-yielding dividend stocks can be great investments to hold on to in your portfolio, but only if they're safe. Betting on a high yield can be dangerous because if it ends up getting cut, you could lose all or most of the dividend income, and the stock may crash in the process as dividend investors could look elsewhere for a high payout.
CHMP Issues Positive Opinion for Label Expansion of BMY's Opdivo
BMY obtains CHMP recommendation for Opdivo for perioperative regimen of neoadjuvant Opdivo and chemotherapy followed by surgery and adjuvant Opdivo for resectable non-small cell lung cancer.
